Eli Lilly unveiled plans for a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, intended to produce its next‑generation obesity injectable retatrutide and other weight‑loss drugs. The investment targets both drug production and device assembly to support scaled launches. Lilly cited surging global demand for incretin‑class therapies and prioritized domestic capacity to shorten supply chains and ensure consistent commercial supply. The plant will also provide flexibility to manufacture multiple injectable platforms as new molecules progress to market. The announcement signals incumbents’ heavy capital commitment to secure manufacturing throughput for obesity therapeutics and will influence supply‑chain planning for contract manufacturers, device suppliers and regional fill‑finish capabilities.